Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Ziaderm Research LLC

Neither a doctor nor a teaching hospital

Research payments

$991,200

77 payments

Through program year 2025, Ziaderm Research LLC is reported as receiving $991,200 in research payments, across 77 payments.

By program year

3 rows
Year Kind Amount Payments
2025 Research $570,115 42
2024 Research $384,643 30
2023 Research $36,442 5

Breakdown

Who paid Research payments · program years 2023–2025
  1. Janssen Research & Development, LLC $300,812 20 payments
  2. Sanofi US Services Inc. $229,810 18 payments
  3. AbbVie, Inc. $209,972 21 payments
  4. Novartis Pharmaceuticals Corporation $140,129 3 payments
  5. Pfizer Inc. $47,763 6 payments
  6. Acrotech Biopharma LLC $43,043 6 payments
  7. Eli Lilly and Company $19,671 3 payments
Studies the money was for Research payments · program years 2023–2025
  1. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis $257,809 18 payments
  2. A Multinational, Multicenter, Double-blind, Placebo-controlled Phase 2 Study to Evaluate Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Atopic Dermatitis $175,017 8 payments
  3. A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $95,841 9 payments
  4. A 12-week randomized, participant and investigator-blinded, placebo-controlled, exploratory study in adult participants with Chronic Urticaria to assess the Efficacy and Safety and explore the Mechanism of Action of remibrutinib (LOU064) $75,907 1 payment
  5. A Parallel-group Treatment, Phase 2, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR444656 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa $54,794 10 payments
  6. A Phase 2 Randomized Doubleblind Placebocontrolled Study to Investigate the Efficacy and Safety of Pf07275315 and Pf07264660 in Adult Participants With Moderatesevere Atopic Dermatitis $47,763 6 payments
  7. A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants with Moderate to Severe Plaque Psoriasis with Randomized Withdrawal and Retreatment $43,003 2 payments
  8. A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa $36,798 1 payment
  9. 246-13651-302 $35,619 4 payments
  10. 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years S $35,340 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record